TBK1/IKK(epsilon)-IN-2

• CAT Number: I013863
• CAS Number: 1292310-49-6
• Molecular Formula: C₂₆H₂₇N₅O₃
• Molecular Weight: 457.52
• Purity: ≥95%
• Target: IKK
• Solubility: DMSO: 21.5 mg/mL
• IUPAC Name: 5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-2-(oxan-4-yloxy)benzonitrile
• InChI: InChI=1S/C26H27N5O3/c27-18-20-17-19(1-6-25(20)34-23-8-13-32-14-9-23)24-7-10-28-26(30-24)29-21-2-4-22(5-3-21)31-11-15-33-16-12-31/h1-7,10,17,23H,8-9,11-16H2,(H,28,29,30)
• InChIKey: BWABTWGSXHTHCG-UHFFFAOYSA-N
• SMILES: C1COCCC1OC2=C(C=C(C=C2)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCOCC5)C#N

TBK1/IKKε-IN-2（Cat No.:）is a selective small molecule inhibitor targeting two critical kinases: TANK-binding kinase 1 (TBK1) and IκB kinase epsilon (IKKε). Both kinases are involved in regulating immune responses, inflammation, and cellular stress pathways. TBK1 plays a role in the antiviral response and innate immunity, while IKKε is involved in the activation of NF-κB, a key transcription factor in inflammation. By inhibiting both kinases, TBK1/IKKε-IN-2 may have therapeutic potential in treating inflammatory diseases, autoimmune disorders, and cancer. Preclinical studies suggest its efficacy, though further clinical trials are needed to assess safety and therapeutic benefits.

Reference

[1]. Muvaffak A, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res. 2014 Jul;12(7):1055-66.